Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 4, 2014, Pages 501-506

  Pedrazzoli, Paolo ^a   Martinelli, Giovanni ^b   Gianni, Alessandro Massimo ^c   Da Prada, Gian Antonio ^d   Ballestrero, Alberto ^e   Rosti, Giovanni ^f,o   Frassineti, Giovanni Luca ^g   Aieta, Michele ^h,p   Secondino, Simona ^a,i   Cinieri, Saverio ^b,q   Fedele, Roberta ^j   Bengala, Carmelo ^k,r   Bregni, Marco ^l,s   Grasso, Donatella ^a   De Giorgi, Ugo ^g   Lanza, Francesco ^m   Castagna, Luca ⁿ   Bruno, Barbara ^e   Martino, Massimo ^j  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Civil Hospital   (Italy)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k UNIVERSITY HOSPITAL OF PISA   (Italy)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m Section of Hematology and Bone Marrow Transplant Unit   (Italy)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^o CA FONCELLO HOSPITAL   (Italy)

^p REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^q A Perrino Hospital   (Italy)

^r MISERICORDIA HOSPITAL   (Italy)

^s Circolo Hospital   (Italy)

more..

Author keywords

Autologous hematopoietic progenitor cell support; High dose chemotherapy; High risk breast cancer

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; MELPHALAN; MITOXANTRONE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; ITALY; LONG TERM SURVIVAL; LYMPH NODE; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; PREMENOPAUSE; RISK; SURVIVAL RATE; TUMOR VOLUME; YOUNG ADULT;

AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL SUPPORT; HIGH-DOSE CHEMOTHERAPY; HIGH-RISK BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GENE EXPRESSION; HUMANS; ITALY; LYMPHATIC METASTASIS; MIDDLE AGED; MITOXANTRONE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTOR, ERBB-2; REGISTRIES; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84895818881     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.12.569     Document Type: Article

References (33)

1. Hryniuk W., Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. JClin Oncol 1986, 4:1162-1170.
2. Bonadonna G., Valagussa P., Tancini G., et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1986, (1):45-49.
3. Pedrazzoli P., Ferrante P., Kulekci A., et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003, 32:489-494.
4. Pedrazzoli P., Rosti G., Secondino S., et al. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol 2007, 44:286-295.
5. Nitz U.A., Mohrmann S., Fischer J., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet 2005, 366:1935-1944.
6. Rodenhuis S., Bontenbal M., van Hoesel Q.G., et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006, 17:588-596.
7. Moebus V., Jackisch C., Lueck H.J., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. JClini Oncol 2010, 28:2874-2880.
8. Berry D.A., Ueno N.T., Johnson M.M., et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. JClin Oncol 2011, 29:3214-3223.
9. Nieto Y., Shpall E.J. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr Opin Oncol 2009, 21:150-157.
10. Gluz O., Mengele K., Schmitt M., et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. JClin Oncol 2009, 27:6144-6151.
11. Martino M., Bottini A., Rosti G., et al. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opin Biol Ther 2012, 12:1505-1515.
12. De Giorgi U., Amadori D. Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. JClin Oncol 2012, 30:758.
13. Moroni M. High-dose chemotherapy as adjuvant therapy in breast cancer: could there be a survival benefit?. JClin Oncol 2012, 30:759.
14. Wang J., Zhang Q., Zhou R., et al. High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis. PLoS One 2012, 7:e33388.
15. Basser R.L., O'Neill A., Martinelli G., et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. JClin Oncol 2006, 24:370-378.
16. Rodenhuis S., Bontenbal M., Beex L.V., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. NEngl J Med 2003, 349:7-16.
17. Moore H.C., Green S.J., Gralow J.R., et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. JClin Oncol 2007, 25:1677-1682.
18. Gianni A.M., Siena S., Bregni M., et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. JClin Oncol 1997, 15:2312-2321.
19. Peters W.P., Rosner G.L., Vredenburgh J.J., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versusintermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. JClin Oncol 2005, 23:2191-2200.
20. Peters W.P., Ross M., Vredenburgh J.J., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. JClin Oncol 1993, 11:1132-1143.
21. Tallman M.S., Gray R., Robert N.J., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. NEngl J Med 2003, 349:17-26.
22. Antman K.H., Rowlings P.A., Vaughan W.P., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. JClin Oncol 1997, 15:1870-1879.
23. Damon L.E., Hu W.W., Stockerl-Goldstein K.E., et al. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant 2000, 6:496-505.
24. Marino P., Roché H., Moatti J.P. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment usinga quality-adjusted survival analysis. Am J Clin Oncol 2008, 31:117-124.
25. Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995, 273:542-547.
26. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. NEngl J Med 2005, 352:2302-2313.
27. Gluz O., Nitz U.A., Harbeck N., et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of the WSG AM-01 trial. Ann Oncol 2008, 19:861-870.
28. De Giorgi U., Rosti G., Frassineti L., et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 2007, 18:202-203.
29. Crown J., Wassherheit C., Hakes T., et al. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. JNatl Cancer Inst 1992, 84:1935-1936.
30. Roche H., Viens P., Biron P., et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003, 10:42-47.
31. Tokuda Y., Tajima T., Narabayashi M., et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 2008, 99:145-151.
32. Martino M., Montanari M., Bruno B., et al. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opin Biol Ther 2012, 12:1449-1462.
33. Meisenberg B.R., Ferran K., Hollenbach K., et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998, 21:927-932.